Alzheimer Disease, Early Onset
57
18
26
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.8%
1 terminated out of 57 trials
92.9%
+6.4% vs benchmark
4%
2 trials in Phase 3/4
15%
2 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (57)
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Cholinergic Deep Brain Stimulation for Alzheimer's Disease
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease
Theta-burst Stimulation on Cognitive Function in the Patients With Young-onset Alzheimer's Disease Dementia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
The Ketogenic Diet for Alzheimer's Disease
Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
A Study to Assess THN391 in Subjects With Alzheimer's Disease
Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE
SNIFF - 3-Week Aptar CPS Device
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Neuropsychological Evaluation in Intellectual Disability (ENDI)